Celgene Corporation announced organizational changes that will position the Company for continued long-term growth. Effective March 1, 2016. Bob Hugin to serve as Executive Chairman.

Bob Hugin will continue to lead the Board of Directors and manage the strategic direction of the company. Mark Alles will be promoted to Chief Executive Officer. Jacqualyn Fouse, PhD, will be promoted to President and Chief Operating Officer.

Scott Smith, President Immunology & Inflammation, will assume an expanded leadership role. Throughout Bob Hugin's nearly 17 years of managerial leadership, Celgene has achieved unprecedented growth and produced outstanding results. As Executive Chairman, Bob Hugin will remain actively involved in key business matters, continuing to direct the long-term future of the company.

Mark is a three-decade industry veteran and has been with Celgene since 2004, most recently serving as President & COO. As President & COO, Mark integrated Celgene's corporate operational functions in support of its global commercial franchises. Jackie joined Celgene in 2010 as Chief Financial Officer and has excelled as both the leader of Celgene's Finance department and in her current role as President of Celgene's Hematology & Oncology franchise.